{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:51:38Z","timestamp":1781866298688,"version":"3.54.5"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Many patients hospitalized with acute heart failure (AHF) do not respond adequately to initial intravenous loop diuretic therapy, and residual congestion at discharge is associated with adverse outcomes. We conducted a systematic review and meta-analysis of randomized controlled trials comparing loop diuretics alone versus loop diuretics in combination with add-on pharmacotherapy in adults hospitalized with AHF. PubMed, Embase, and CENTRAL were searched from inception to May 7, 2025. Efficacy outcomes included mortality, hospital readmission, hospital length of stay (LOS), change in body weight, and urine output (UO). Safety outcomes included worsening renal function, worsening heart failure (WHF), hypokalemia, and serious adverse events. Twenty-four randomized studies were identified, with 22 included in the meta-analysis. Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduced mortality [risk ratio (RR), 0.60 (95% confidence interval [CI], 0.38\u20130.94)], WHF [RR, 0.64 (95% CI, 0.43\u20130.96)], serious adverse events [RR, 0.74 (95% CI, 0.60\u20130.92)], and body weight [mean difference (MD), \u22121.05 (95% CI, \u22121.97 to \u22120.13) kg]. Tolvaptan was associated with greater weight reduction [MD, \u22120.98 (95% CI, \u22121.25 to \u22120.70) kg] and increased UO [MD, 1.15 (95% CI, 0.16\u20132.14) L]. Add-on hydrochlorothiazide (HCTZ) increased UO [MD, 0.95 (95% CI, 0.47\u20131.43) L] and decreased LOS [MD, \u22121.38 (95% CI, \u22122.40 to \u22120.36) days] but increased the risk of worsening renal function [RR, 2.03 (95% CI, 1.10\u20133.74)] and hypokalemia [RR, 2.31 (95% CI, 1.51\u20133.52)]. Overall, the combination with SGLT2 inhibitors, tolvaptan, and HCTZ improved surrogate markers of decongestion in AHF. SGLT2 inhibitors were associated with reduced mortality and WHF, whereas HCTZ shortened hospital LOS but increased the risk of renal dysfunction and hypokalemia.<\/jats:p>","DOI":"10.1097\/crd.0000000000001337","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:00:28Z","timestamp":1781722828000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Combination Pharmacotherapies With Standard Diuretic Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Alexander","family":"Leaman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH"},{"name":"Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad T.","family":"Alashqar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH"},{"name":"Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"R1-20260619","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R2-20260619","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/0885066616669494","article-title":"Acute decompensated heart failure.","volume":"33","author":"Hammond","year":"2018","journal-title":"J Intensive Care Med"},{"key":"R3-20260619","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2020.12.020","article-title":"Cost of inpatient heart failure care and 30-day readmissions in the United States.","volume":"329","author":"Kwok","year":"2021","journal-title":"Int J Cardiol"},{"key":"R4-20260619","article-title":"Forecasting the impact of heart failure in the United States.","journal-title":"Circ Heart Fail"},{"key":"R5-20260619","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"R6-20260619","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure.","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20260619","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure.","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-20260619","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function.","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"R9-20260619","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure.","volume":"56","author":"Jentzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R10-20260619","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","article-title":"Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial.","volume":"8","author":"Cox","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R11-20260619","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1074248413482755","article-title":"Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.","volume":"18","author":"Ng","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R12-20260619","doi-asserted-by":"crossref","first-page":"21A","DOI":"10.1016\/0002-9149(93)90241-4","article-title":"Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.","volume":"71","author":"van Vliet","year":"1993","journal-title":"Am J Cardiol"},{"key":"R13-20260619","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R14-20260619","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload.","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"R15-20260619","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload.","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R16-20260619","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"R17-20260619","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R18-20260619","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/phar.2440","article-title":"A systematic review and meta-analysis of metolazone compared to chlorothiazide for treatment of acute decompensated heart failure.","volume":"40","author":"Steuber","year":"2020","journal-title":"Pharmacotherapy"},{"key":"R19-20260619","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/anae.14038","article-title":"Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials.","volume":"73","author":"Ng","year":"2018","journal-title":"Anaesthesia"},{"key":"R20-20260619","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40256-024-00633-9","article-title":"Acetazolamide as an combinationdiuretic therapy for patients with acute decompensated heart failure: a systematic review and meta-analysis.","volume":"24","author":"Siddiqi","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"R21-20260619","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00392-022-02148-2","article-title":"Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.","volume":"112","author":"Carvalho","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"R22-20260619","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2025.08.041","article-title":"Efficacy and safety of different combinations of add-on diuretic therapy in acute heart failure: a systematic review and network meta-analysis of randomized controlled trials.","volume":"258","author":"Sephien","year":"2026","journal-title":"Am J Cardiol"},{"key":"R23-20260619","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"R24-20260619","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure.","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R26-20260619","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure.","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R27-20260619","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1253\/circrep.CR-19-0064","article-title":"Long-term tolvaptan treatment in refractory heart failure.","volume":"1","author":"Imamura","year":"2019","journal-title":"Circ Rep"},{"key":"R28-20260619","first-page":"700","article-title":"The efficacy and safety of short-term tolvaptan usage in patients with acute decompensated heart failure.","volume":"38","author":"Lin","year":"2022","journal-title":"Acta Cardiol Sin"},{"issue":"Suppl 1","key":"R29-20260619","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ihj.2015.07.006","article-title":"Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.","volume":"68","author":"Shanmugam","year":"2016","journal-title":"Indian Heart J"},{"key":"R30-20260619","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study.","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"R31-20260619","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials.","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"R32-20260619","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"R33-20260619","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R34-20260619","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF).","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"R35-20260619","doi-asserted-by":"crossref","first-page":"e007048","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study.","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R36-20260619","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ehf2.13955","article-title":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.","volume":"9","author":"Thiele","year":"2022","journal-title":"ESC Heart Failure"},{"issue":"4","key":"R37-20260619","first-page":"S715","article-title":"Effect of Sglt2 inhibitor dapagliflozin on sodium, potassium and creatinine levels in patients with acute heart failure.","volume":"35 Suppl 1","author":"Fatima Gilani","year":"2023","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"R38-20260619","doi-asserted-by":"crossref","first-page":"176179","DOI":"10.1016\/j.ejphar.2023.176179","article-title":"The clinical outcomes of dapagliflozin in patients with acute heart failure: a randomized controlled trial (DAPA-RESPONSE-AHF).","volume":"961","author":"Emara","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"R39-20260619","doi-asserted-by":"crossref","first-page":"602251","DOI":"10.3389\/fcvm.2020.602251","article-title":"Safety and efficacy of adding dapagliflozin to furosemide in type 2 diabetic patients with decompensated heart failure and reduced ejection fraction.","volume":"7","author":"Ibrahim","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"R40-20260619","doi-asserted-by":"crossref","first-page":"e001936","DOI":"10.1136\/openhrt-2021-001936","article-title":"Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.","volume":"9","author":"Charaya","year":"2022","journal-title":"Open Heart"},{"key":"R41-20260619","first-page":"16526","article-title":"Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study.","volume":"133","author":"Kosiorek","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"R42-20260619","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","article-title":"Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study.","volume":"37","author":"Imiela","year":"2017","journal-title":"Clin Drug Investig"},{"key":"R43-20260619","doi-asserted-by":"crossref","first-page":"16474","DOI":"10.1038\/s41598-021-96002-6","article-title":"Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: a randomized clinical trial.","volume":"11","author":"Piardi","year":"2021","journal-title":"Sci Rep"},{"key":"R44-20260619","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial.","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"Suppl 4","key":"R46-20260619","first-page":"19","article-title":"Tolvaptan plus low-dose furosemide compared with titrating furosemide in acute decompensated heart failure patients who does not response to initial furosemide dose.","volume":"25","author":"Pratyarattananon","year":"2020","journal-title":"Nephrology"},{"issue":"suppl 1","key":"R47-20260619","article-title":"Effect of intravenous vasodilators on short-term outcome in patients hospitalized for acute heart failure.","volume":"37","author":"Farmakis","year":"2016","journal-title":"Eur Heart J"},{"issue":"suppl_1","key":"R49-20260619","doi-asserted-by":"crossref","first-page":"ehy563.4363","DOI":"10.1093\/eurheartj\/ehy563.4363","article-title":"4363Do acetazolamide and spironolactone increase natriuresis in congestive heart failure?","volume":"39","author":"Verbrugge","year":"2018","journal-title":"Eur Heart J"},{"issue":"16 Suppl","key":"R50-20260619","doi-asserted-by":"crossref","first-page":"C230","DOI":"10.1016\/j.jacc.2015.06.885","article-title":"GW26-e0494 Effectiveness and safety of tolvaptan in Chinese heart failure patients with reduced left ventricular systolic function.","volume":"66","author":"Zeng","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_1","key":"R51-20260619","doi-asserted-by":"crossref","first-page":"ehz746.0371","DOI":"10.1093\/eurheartj\/ehz746.0371","article-title":"P5413Effect of empagliflozin as add-on therapy on serum uric acid level in patients with type 2 diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study.","volume":"40","author":"Tamaki","year":"2019","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"R52-20260619","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled study for efficacy and safety of short-term tolvaptan usage in patients with acute decompensated heart failure.","volume":"17","author":"Lin","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"suppl 1","key":"R53-20260619","article-title":"Impact of furosemide dosages on in-hospital and post-discharge outcomes in acute heart failure diabetic patients: a DAD-HF II sub-study.","volume":"37","author":"Giamouzis","year":"2016","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"R54-20260619","first-page":"zuab020.026","article-title":"Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: a randomized clinical trial.","volume":"10","author":"Piardi","year":"2021","journal-title":"Euro Heart JAcut Cardiovasc Care"},{"issue":"Suppl 1","key":"R55-20260619","first-page":"S715","article-title":"Effect of Sglt2 inhibitor dapagliflozin on sodium, potassium and creatinine levels in patients with acute heart failure.","volume":"35","author":"Fatima Gilani","year":"2023","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"Supplement_1","key":"R56-20260619","doi-asserted-by":"crossref","first-page":"ehz745.0167","DOI":"10.1093\/eurheartj\/ehz745.0167","article-title":"4330Effect of empagliflozin as add-on therapy on decongestion and renal function in diabetic patients hospitalized for acute decompensated heart failure: a prospective randomized controlled study.","volume":"40","author":"Tamaki","year":"2019","journal-title":"Eur Heart J"},{"key":"R57-20260619","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cardfail.2022.10.323","article-title":"Impact of dapagliflozin treatment on serum sodium concentration in acute decompensated heart failure.","volume":"29","author":"Charaya","year":"2023","journal-title":"J Card Fail"},{"issue":"8, Supplement","key":"R58-20260619","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.cardfail.2019.07.229","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.","volume":"25","author":"Verbrugge","year":"2019","journal-title":"J Card Fail"},{"key":"R60-20260619","doi-asserted-by":"crossref","first-page":"621","DOI":"10.47391\/JPMA.9813","article-title":"Early initiation of Dapagliflozin and its effect on health related quality of life in acute heart failure: a randomised controlled trial.","volume":"74","author":"Fatima Gilani","year":"2024","journal-title":"J Pak Med Assoc"},{"issue":"Supplement_2","key":"R61-20260619","doi-asserted-by":"crossref","first-page":"ehaa946.1228","DOI":"10.1093\/ehjci\/ehaa946.1228","article-title":"Effect of empagliflozin as add-on therapy on transtubular potassium concentration gradient in patients with type 2 diabetes hospitalized for acute decompensated heart failure.","volume":"41","author":"Tamaki","year":"2020","journal-title":"Eur Heart J"},{"key":"R63-20260619","doi-asserted-by":"crossref","first-page":"2373275","DOI":"10.1080\/0886022X.2024.2373275","article-title":"SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure.","volume":"46","author":"Gojaseni","year":"2024","journal-title":"Ren Fail"},{"key":"R64-20260619","doi-asserted-by":"crossref","first-page":"126","DOI":"10.20996\/1819-6446-2023-03-02","article-title":"Clinical efficacy and safety of empagliflozin in patients with acute heart failure from the first day of hospitalization.","volume":"19","author":"Golubovskaya","year":"2023","journal-title":"Ration Pharmacother Cardiol"},{"issue":"suppl E","key":"R65-20260619","first-page":"E14","article-title":"Effect of early spironolactone therapy to the ST2 level and clinical changes in patient with acute decompensated heart failure.","volume":"19","author":"Mufidah","year":"2017","journal-title":"Eur Heart J Suppl"},{"key":"R66-20260619","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","article-title":"Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.","volume":"8","author":"Asakura","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R67-20260619","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment - results from the K-STAR study.","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"},{"key":"R68-20260619","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"R69-20260619","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jacc.2010.11.057","article-title":"Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (placebo-controlled randomized study of the selective adenosine A1 receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function).","volume":"57","author":"Voors","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R70-20260619","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J Card Fail"},{"key":"R71-20260619","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.197","article-title":"Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.","volume":"53","author":"Suzuki","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R72-20260619","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jjcc.2020.05.012","article-title":"Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.","volume":"76","author":"Takagi","year":"2020","journal-title":"J Cardiol"},{"key":"R73-20260619","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/00015385.2018.1455947","article-title":"Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome.","volume":"74","author":"Verbrugge","year":"2019","journal-title":"Acta Cardiol"},{"key":"R74-20260619","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"R75-20260619","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"R76-20260619","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R77-20260619","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R78-20260619","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 Inhibitors in heart failure and their clinical value.","volume":"81","author":"Xie","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"R79-20260619","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12872-017-0598-y","article-title":"Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"R80-20260619","first-page":"2971","article-title":"Comparison of diuretic strategies in diuretic-resistant acute heart failure: a systematic review and network meta-analysis.","volume":"25","author":"Orso","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R81-20260619","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ejhf.1802","article-title":"Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.","volume":"22","author":"de Denus","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R82-20260619","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry.","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R83-20260619","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2024.4489","article-title":"Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction.","volume":"10","author":"Abdel Jawad","year":"2025","journal-title":"JAMA Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:00:21Z","timestamp":1781863221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001337","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}